{"id":"NCT02576860","sponsor":"Maruho Co., Ltd.","briefTitle":"Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle","officialTitle":"A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea With a 4 Week Follow-up Period","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10","primaryCompletion":"2017-02-27","completion":"2017-09-05","firstPosted":"2015-10-15","resultsPosted":"2022-07-08","lastUpdate":"2022-08-02"},"enrollment":263,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rosacea"],"interventions":[{"type":"DRUG","name":"CLS001 (Omiganan)","otherNames":[]},{"type":"DRUG","name":"Vehicle","otherNames":[]}],"arms":[{"label":"Treatment","type":"EXPERIMENTAL"},{"label":"Vehicle Gel","type":"PLACEBO_COMPARATOR"}],"summary":"This study evaluates the safety and efficacy of once-daily application of CLS001 topical gel compared to vehicle gel in subjects with severe papulopustular rosacea.","primaryOutcome":{"measure":"Efficacy Absolute Change in Inflammatory Lesion Count","timeFrame":"12 weeks","effectByArm":[{"arm":"Treatment","deltaMin":-19.8,"sd":2.29},{"arm":"Vehicle Gel","deltaMin":-20.9,"sd":2.36}],"pValues":[{"comp":"OG000 vs OG001","p":"0.799"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":47,"countries":["United States","Australia","Canada","France","Germany","Netherlands","New Zealand","Sweden","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":136},"commonTop":["Viral upper respiratory tract infection","Headache","Application site pain","Application site erythema","Application site pruritus"]}}